emory university school of medicine standard … t. sellers md_cv.pdfemory university school of...

Marty Thomas Sellers April 13, 2018 1

EMORY UNIVERSITY SCHOOL OF MEDICINE STANDARD CURRICULUM VITAE FORMAT

Revised: March 27, 2018

1. NAME: Marty Thomas Sellers, MD MPH

2. OFFICE ADDRESS: 1365 Clifton Road NE (Suite B6300)

Atlanta, Georgia 30322 TEL: 404-712-9910 FAX: 404-778-5033

3. E-mail Address: [email protected]

4. Citizenship: United States

5. Current Titles and Affiliations:

a. Academic Appointments:

i. Primary Appointments: Assistant Professor of Surgery

Division of Gastrointestinal and General Surgery

Emory University School of Medicine 2016 – present

b. Clinical Appointments: Attending Surgeon, Emory University Hospital

2016 – present

Attending Surgeon, Emory University Hospital-Midtown 2016 – present Attending Surgeon, Emory Saint Joseph’s Hospital 2016 – present Attending Surgeon, Atlanta VA Medical Center 2017 – present Associate Medical Director, LifeLink of Georgia 2014 – present [LifeLink of Georgia is the 4th busiest (of 58) organ procurement organizations (OPOs) in the United States and oversees donor management of (and allocation of organs from) deceased organ donors


from all of Georgia and a portion of South Carolina.]

6. Previous Academic and Professional Appointments:

1. Instructor in Transplantation Surgery

University of Pennsylvania School of Medicine 1995 – 1997

2. Assistant Professor of Surgery Division of Transplantation University of Alabama School of Medicine 1997 – 2002

3. Associate Scientist Comprehensive Cancer Center, Chemoprevention Program University of Alabama School of Medicine 2001 – 2002

4. Associate Professor of Surgery Division of Transplantation University of Alabama School of Medicine 2001 – 2002

5. Assistant Professor of Surgery Division of Transplantation University of Pennsylvania School of Medicine 2002 – 2005

6. Associate Professor of Surgery Division of Transplantation University of Pennsylvania School of Medicine 2005

7. Clinical Associate Professor of Surgery Mercer University 2008 – 2015

8. Clinical Assistant Professor of Surgery Division of Transplantation University of Pittsburgh School of Medicine 2015 – 2016

7. Previous Administrative and/or Clinical Appointments:

1. Attending Multiorgan Transplant Surgeon


University of Alabama Hospital 1997 – 2002


The Children’s Hospital of Alabama 1997 – 2002

3. Attending Surgeon

Birmingham VA Medical Center 1997 – 2002

4. Attending Physician Comprehensive Cancer Center – Chemoprevention Program University of Alabama at Birmingham 2001 – 2002

5. Attending Multiorgan Transplant Surgeon Children’s Hospital of Philadelphia 2002 – 2005

6. Attending Multiorgan Transplant Surgeon Hospital of the University of Pennsylvania 2002 – 2005

7. Surgical Director, Renal Transplantation Children’s Hospital of Philadelphia 2002 – 2005

8. Multiorgan Transplant and Hepatobiliary Surgeon Piedmont Transplant Institute, Piedmont Atlanta Hospital 2005 – 2015

9. Director, Hepatobiliary Service Piedmont Atlanta Hospital 2007 – 2015

10. Attending Multiorgan and Hepatobiliary Transplant Surgeon Memorial Health-University Medical Center 2007 – 2015

11. Attending Multiorgan Transplant Surgeon Starzl Transplant Institute UPMC Presbyterian 2015 – 2016



Starzl Transplant Institute Children’s Hospital of Pittsburgh 2015 – 2016

13. Attending Renal Transplant Surgeon Starzl Transplant Institute UPMC Hamot 2015 – 2016

8. Licensures: Alabama 14823 (1989 – 2003, voluntarily inactive) Pennsylvania MD420413 (2002 – present) Georgia 56925 (2005 – present)

9. Specialty Boards: American Board of Surgery, 41454, Pennsylvania, 1996,

2007, 2016

10. Education: 1980 – 1984 Bachelor of Science (Biology) Auburn University Auburn, Alabama 1984 – 1988 Doctorate of Medicine University of Alabama School of Medicine Birmingham, Alabama 2009 – 2013 Master of Public Health (Healthcare Outcomes)

Rollins School of Public Health, Emory University

Atlanta, Georgia

11. Postgraduate Training:

Internship – General Surgery, 1988-1989 University of Alabama School of Medicine Birmingham, Alabama Arnold G. Diethelm (Chairman and Director)

Residency – General Surgery, 1989-1991, 1993-1995 Administrative Chief Resident, 1994-1995 University of Alabama School of Medicine Birmingham, Alabama Arnold G. Diethelm (Chairman, Director 1989-1993) Marshall M. Urist (Director, 1994-1995)

Research Fellowship – Surgical Oncology National Research Service Award (T32 CA 009617-05),


1991-1993 National Institutes of Health

University of Alabama School of Medicine Birmingham, Alabama

Marshall M. Urist (Mentor) Clinical Research Training Program, 1999-2001 National Institutes of Health (K30) University of Alabama School of Medicine Birmingham, Alabama Arnold G. Diethelm (Mentor) Clinical Fellowship – Abdominal Transplant Surgery, 1995-1997

Hospital of the University of Pennsylvania The Children’s Hospital of Philadelphia Philadelphia, Pennsylvania, USA Clyde F. Barker (Chairman and Director)

12. Continuing Professional Development Activities:

Piedmont Leadership Academy, 2012

13. Committee Memberships:

a. National and International:

1. The Organ Procurement and Transplantation Network/United Network of Organ Sharing (OPTN/UNOS) [Federal government entity that oversees accreditation of all solid organ transplant programs and organ procurement organizations in the United States] Pediatric Committee, 2004-2006

Leader of Kidney Working Group, 2005-2006

2. OPTN/UNOS Subcommittee to initiate standardization and formal tracking of utilization of vessels obtained from cadaveric organ donors, 2004

3. OPTN/UNOS Subcommittee on Membership Criteria Review for Pediatric Transplant Programs and Surgeons/Physicians, 2004-2005

4. OPTN/UNOS Joint Pediatric-OPO-Ad Hoc Operations Subcommittee on EBV Testing, Pediatric Committee Representative, 2004-2005

5. OPTN/UNOS Joint Pediatric-Liver/Intestine-Ad Hoc Subcommittee on Pediatric Liver Transplant Program Criteria Review, Pediatric Committee Representative, 2004-2005


6. OPTN/UNOS Ethics Committee, Region 3 Representative, 2013-2016 Leader of Working Group revising White Paper on Split Liver Transplantation, 2015-2016

7. OPTN/UNOS Joint Ethics-Kidney-Liver/Intestine-Ad Hoc Subcommittee on Simultaneous Liver-Kidney (SLK) Transplantation, Ethics Committee Representative, 2014-2016

8. OPTN/UNOS OPO Committee, Region 3 Representative, 2017-2020.

b. Regional:

1. The Gift of Life Donor Program [Gift of Life Donor Program is the busiest

OPO in the United States that oversees management of and allocation of organs from deceased organ donors from all of Delaware, eastern half of Pennsylvania and southern New Jersey], Kidney-Pancreas Committee, 2002-2005

2. LifeLink of Georgia, Advisory Board, 2009-2011 [charged with ensuring compliance with federal regulations and statutes regarding deceased organ donation]

3. LifeLink of Georgia, Professional Development and Clinical Practice Committee, 2009-2014 [charged with developing strategies to maximize organ donation potential from hospitals within the OPO’s service area]

4. LifeLink Foundation Board of Governors, 2013-present. [[LifeLink Foundation

is comprised by 3 OPOs with a >$100 million annual operating budget: LifeLink of Georgia, LifeLink of Florida and LifeLink of Puerto Rico. I am a member of their corporate board, responsible for large-scale oversight of the execution of their mission.

5. LifeLink Foundation, Medical Advisory Committee 2014-present [The Medical Advisory Committee establishes and re-evaluates medical criteria for deceased organ donor management and recovery.]

6. LifeLink Foundation, Publications Committee 2016-present; Chairman

c. Institutional:

1. Chemoprevention Committee, University of Alabama at Birmingham Comprehensive Cancer Center, 2001-2002

2. Piedmont Atlanta Hospital Cancer Committee, 2007-2015 3. Piedmont Atlanta Hospital Oncology Scientific Review Committee, 2008-

2015


4. Piedmont Atlanta Hospital Surgical Care and Evaluation Committee, 2008-2011

5. Piedmont Atlanta Hospital Cancer Center Operations Council, 2009-2015 6. Piedmont Atlanta Hospital Advisory Council for Research, 2010-2015 7. Piedmont Atlanta Hospital Branding Advisory Board, 2011-2012 8. Piedmont Atlanta Hospital Performance Improvement Council, 2013-2015 9. Piedmont Atlanta Hospital Oncology Physician Council, 2014-2015 10. Rollins School of Public Health Alumni Board – Career Development

Committee, 2016-2017. 11. Rollins School of Public Health Alumni Board – Alumni Giving Committee,

2017-2018. 12. Emory University Hospital eConsent Selection Committee, 2017.

14. Peer Review Activities:

a. Manuscripts:

1. American Journal of Transplantation – 2003, 2004, 2016, 2017, 2018 2. Journal of the Institute for Laboratory Animal Research, National Academy of

Sciences – 2003 3. Liver Transplantation – 2006, 2017, 2018 4. Journal of Surgical Research – 2006, 2007 5. Journal of the American College of Surgeons – 2011 6. Clinical Transplantation – 2016, 2017, 2018 7. Transplantation – 2017, 2018 8. Surgical Laparoscopy Endoscopy & Percutaneous Techniques – 2017 9. Surgery for Obesity and Related Diseases – 2018

b. Conference Abstracts:

i. National and International:

1. Twenty-sixth Annual Scientific Meeting of the American Society of Transplant

Surgeons, Chicago, Illinois, 2000 2. First American Transplant Congress, Chicago, Illinois, 2001 3. Second American Transplant Congress, Washington, DC, 2002 4. Third American Transplant Congress, Washington, DC, 2003 5. Fourth American Transplant Congress, Washington, DC, 2004 6. Fifth American Transplant Congress, Seattle, Washington, 2005 7. Eighth American Transplant Congress, Toronto, ON, Canada, 2008 8. Ninth American Transplant Congress, Boston, Massachusetts, 2009 9. Tenth American Transplant Congress, San Diego, California, 2010 10. Eleventh American Transplant Congress, Philadelphia, Pennsylvania 2011 11. Twelfth American Transplant Congress, Boston Massachusetts, 2012

15. Consultantships:


1. Roche Pharmaceuticals Northeast Regional Liver Advisory Board, 2003 2. Onyx Pharmaceuticals® Hepatocellular Carcinoma Advisory Board, 2013 3. Bayer Healthcare Hepatocellular Carcinoma Advisory Board, 2011, 2016 4. Aim Specialty Services, Consultant 2014-present 5. Sirtex® Hepatocellular Carcinoma Advisory Board, 2016

16. Editorships and Editorial Boards:

1. Assistant Editor, Chimera, quarterly newsletter for the American Society of

Transplant Surgeons, 2004-2005

2. Associate Editor, Clinical Transplantation, 2017-present. 17. Honors and Awards:

1. Cum laude, Auburn University, 1984 2. Magna cum laude, University of Alabama School of Medicine, 1988 3. Upjohn Travel Award, American Association for Cancer Research, 1994 4. Joseph M. Donald Memorial Award for best research paper, Alabama

Chapter of American College of Surgeons, 1994 5. Award for best oral presentation, First Place, Surgery Section, Eighty-eighth

Annual Scientific Assembly of the Southern Medical Association, 1994 6. Quality and Patient Safety Award, Clinical Effectiveness and Quality

Improvement Initiative, University of Pennsylvania Health System, 2005. Project: Improved Outcomes in Renal Transplantation in Terms of Kidney Function, Patient Morbidity and Cost-efficiency: Results of a Collaborative Effort to Reduce Allograft Ischemia

7. Montague Boyd Award for best clinical case report by a Piedmont physician, 2007, 2009.

8. Magna cum laude, Emory University, 2013. 9. Delta Omega Public Health Honor Society, 2013. [Organization to “encourage

and recognize excellence in practice, research, education, and academic achievement in the field of public health.”]

10. Outstanding Practicum Award, Rollins School of Public Health, Emory University, 2013.

11. Award for “Most Outstanding Quality Improvement Intervention” at the Emory Healthcare’s 10th Annual Quality Conference, June 1, 2017.

18. Society Memberships: 1. American College of Surgeons (Fellow), 1997 - present 2. American Society of Transplant Surgeons, 2002 - present 3. American Hepato-Pancreato-Biliary Association, 2007 - present 4. American Association for the Study of Liver Disease, 2007 - present 5. International Hepato-Pancreato-Biliary Association, 2007 - present 6. International Liver Cancer Association, 2008 - present


19. Organization of Conferences:

a. National and International:

i. Administrative Positions:

Webinar Series Faculty, The Alliance – Leadership in Organ Donation and Transplantation, 2017-2018. [“The Alliance” (http://organdonationalliance.org/wp-content/uploads/2017/05/WebinarFaculty_WorkgroupOutline_Final_052417.pdf is a national non-profit organization “dedicated to providing engaged learning, innovation and collaborative leadership for future advancements in organ donation and transplantation.” My responsibilities include:

• Identify topics and speakers for the webinar series • Serve as a moderator for the webinars • Participate in quarterly, 1-hour workgroup calls • Attend the monthly webinars to assess and evaluate efficacy and ongoing

needs • Coordinate and complete the planning worksheet with the speaker(s) • Review evaluation feedback and consider strategies for future webinars • Help identify marketing strategies of webinars to those who could benefit

from participating

ii. Sessions as Chair:

1. Early Post-transplant and Donor Issues. Fourth American Transplant Conference, Washington DC, 2004.

2. Post-transplant Complications. Fifth American Transplant Conference, Seattle, Washington, 2005.

b. Regional:


Organizer, Moderator, Faculty. “Hepatocellular Carcinoma: A Multidisciplinary Approach.” Georgia Cancer Foundation, Atlanta, Georgia, 2009.

c. Institutional:


1. Organizer, Moderator, Faculty. “Hepatocellular Carcinoma in 2007: Surgical

Management and Outcomes.” Update on Liver and Kidney Disease and


Transplantation, 2007.

2. Organizer, Moderator, Faculty. “Transplantation for Hepatocellular Carcinoma Outside the Milan Criteria.” Update on Liver and Kidney Transplantation: Controversies in Transplantation. 2009.

20. Clinical Service Contributions:

1. Led multidisciplinary, collaborative effort to reduce total ischemic time for expanded criteria deceased donor kidney allografts, resulting in better allograft function, patient morbidity, earlier discharge and overall resource utilization, Hospital of the University of Pennsylvania, 2005. My team won the institutional award for Quality and Patient Safety, Clinical Effectiveness and Quality Improvement Initiative.

2. Established critical care pathway for kidney transplantation, Piedmont Hospital, 2007, resulting in earlier Foley catheter removal and discharge.

3. Founded and was lead physician for Multidisciplinary Hepatocellular Carcinoma (HCC) clinic and weekly HCC-specific conference, Piedmont Hospital, 2006-2015.

a. Designed and implemented process that streamlined patients’ entry

into the clinic and increased the efficiency of care delivery as well as long-term follow-up.

4. Founded and directed Piedmont Hospital Hepatobiliary Service, increasing

total hospital volume for complex hepatobiliary cases from approximately 5 to over 200 per year, 2007-2015.

5. Co-founded and serving as president of Georgia Liver Coalition, Inc., a non-profit organization dedicated to reducing and eliminating deaths from HCC in Georgia residents with chronic liver disease, 2013-present.

6. Assisting with development of Multidisciplinary HCC Clinic at The Atlanta VA

Medical Center, 2017-present.

7. Currently leading a quality initiative to reduce 30-day readmissions after hepato-pancreato-biliary surgery at Emory University Hospital, 2016-present.

21. Community Outreach:

a. Media Appearances:

1. Local (Birmingham, Alabama, WBRC) television station interview during

Organ Donor Awareness Month, April 1999


2. National “Patient Power” radio broadcast: “Liver Transplant Patients and the

Lack of Organ Donors: A Patient’s Story” (https://www.patientpower.info/audio/liver-transplant-patients-and-the-lack-of-organ-donors-a-patients-story). September 11, 2001.

3. Local (Atlanta, Georgia, WSB) television station interview for organ donor

awareness story, 2014

4. National Public Radio’s “Morning Edition” broadcast: “Who Gets First Dibs on Transplanted Liver? Rules May Change.” http://www.npr.org/sections/health-shots/2014/08/14/339579923/who-gets-first-dibs-on-transplanted-liver-rules-may-change. August 14, 2014

5. Reuters News Health article, “’Misperceptions’ Keep Some from Agreeing to

Donate Organs after Death.” Interviewed and quoted in an article about findings in one of my publications on organ donation. https://www.reuters.com/article/us-health-transplants-organ-donors/misperceptions-keep-some-from-agreeing-to-donate-organs-after-death-idUSKBN1FB2S9. January 22, 2018.

22. Formal Teaching: a. Medical Student Teaching:

1. “Importance of Organ Donation.” Lecture to first- and second-year University

of Alabama at Birmingham medical students. October 22, 1998, 1 hour.

2. Course #PHY 750/751 (combined University of Alabama at Birmingham medical/graduate school elective entitled “Clinical and Molecular Physiology and Medicine: Fundamental Insights into Common Diseases”). “Hepatitis C and Liver Transplantation.” Lecture May 25, 1999, 1 hour.

3. “Portal Hypertension.” Lecture to University of Alabama at Birmingham third-year medical students. August 5, 1999, 1 hour.

4. “Anatomy of a Liver Transplant.” Gross Anatomy Course for University of Alabama at Birmingham first-year medical students. Lecture September 3, 1999, 1 hour.

5. “Portal Hypertension.” Lecture to University of Alabama at Birmingham third-year medical students. October 7, 1999, 1 hour.


6. Preceptor for University of Alabama at Birmingham third-year medical students during their surgical clerkship. January 3-February 25, 2000, 3 hours per week.

7. “Portal Hypertension.” Lecture to University of Alabama at Birmingham third-year medical students. January 26, 2000, 1 hour.

8. “Clinical Correlation – Peptic Ulcer Disease, Cholelithiasis, et. al.” Medical Physiology Course, GI Section for University of Alabama at Birmingham first-year medical students. Lecture January 31, 2000, 1 hour.

9. “Peptic Ulcer Disease.” Medical Physiology, GI Section for University of Alabama at Birmingham first-year medical students. Session leader for group discussions. February 2-3, 2000, 4 hours.

10. Preceptor for University of Alabama at Birmingham third-year medical students during their surgical clerkship. February 28-April 22, 2000, 3 hours per week.

11. Medical Physiology/Cell Biology combined project for University of Alabama at Birmingham first-year medical students:

a. Mentor for six students (two groups of three) studying the molecular/physiologic mechanisms of peptic ulcer disease and the molecular/physiologic basis for the diagnostic and therapeutic approaches to peptic ulcer disease – January 3-March 9, 2000, 6 hours per week.

b. All students received the highest grade possible from independent evaluators after their oral presentations of the disease process.

12. “Portal Hypertension.” Lecture to University of Alabama at Birmingham third-

year medical students. March 8, 2000, 1 hour.

13. “Anatomy of a Liver Transplant.” Gross Anatomy Course for University of Alabama at Birmingham first-year medical students. Lecture August 31, 2000, 1 hour.

14. “The Liver Transplant Process.” Combined first- and second-year University of Alabama at Birmingham medical student seminar. Lecture September 12, 2000, 1 hour.

15. Preceptor for University of Alabama at Birmingham third-year medical students during their surgical clerkship. January 8-March 4, 2001, 3 hours per week.


16. “Peptic Ulcer Disease and Liver Failure, et. al.” Medical Physiology Course, GI Section for University of Alabama at Birmingham first-year medical students. Lecture February 5, 2001, 1 hour.

17. Instructor at Suture Workshop for The University of Alabama School of Medicine Surgery Club. February 24, 2001, 2 hours.

18. “Liver Transplantation, Liver Surgery, and Clinical Research in Surgery.” Lecture at The University of Alabama School of Medicine Surgery Club. March 13, 2001, 1 hour.

19. “Transplant/Immunocompromised Patients.” Lecture at the Trauma/Surgical Critical Care Seminar series at The University of Alabama Hospital. March 16, 2001.

20. Preceptor for University of Alabama at Birmingham third-year medical students during their surgical clerkship. May 7–July 1, 2001, 1 hour.

21. Mentor for eight medical students in the UASOM Mentor Program 2001-2002, 30 hours.

22. “Portal Hypertension.” Lecture to University of Alabama at Birmingham third-year medical students. July 23, 2001, 1 hour.

23. Preceptor for University of Alabama at Birmingham third-year medical students during their surgical clerkship. July 5-September 2, 2001, 3 hours per week.

24. “Anatomy of a Liver Transplant.” Gross Anatomy Course for University of Alabama at Birmingham first-year medical students. Lecture September 20, 2001, 1 hour.

25. “Portal Hypertension.” Lecture to University of Alabama at Birmingham third-

year medical students. October 22, 2001, 1 hour.

26. Instructor for University of Alabama at Birmingham first-year medical student Gross Anatomy clinical practicals. October 22-23, 2001, 4 hours.

27. “Portal Hypertension.” Lecture to University of Alabama at Birmingham third-year medical students. December 3, 2001, 1 hour.

28. Preceptor for University of Alabama at Birmingham third-year medical students during their surgical clerkship. January 7, 2002-March 3, 2002, 3 hours per week.


29. “GI Physiology – Clinical Correlation.” Lecture to Medical Physiology Course, GI Section, University of Alabama at Birmingham first-year medical students. February 4, 2002, 1 hour.

30. “Portal Hypertension.” Lecture to University of Alabama at Birmingham third-year medical students March 18, 2002, 1 hour.

31. “Anatomy of Liver Transplantation.” Gross Anatomy Course for University of Alabama at Birmingham first-year medical students. Lecture September 19, 2002, 1 hour.

32. “Transplant Surgery.” Lecture to University of Pennsylvania third-year medical students February 27, 2004, April 30, 2004, August 20, 2004, 1 hour each = 3 total hours.

33. Faculty Facilitator, Interdisciplinary Team Training Day, Emory University, September 26, 2016, 4 hours.

a. Supervised/facilitated enactment of scenarios designed to impart the

importance of collaboration between medical, nursing, advanced nursing, physical therapy, anesthesia assistant disciplines. All participants were first-year students in their respective fields.

34. Guest faculty, Evidence-based Medicine Course, Emory University second-

year medical students, October 11, 2016, 3 hours. a. Supervised discussion of case studies and critique of their scientific merit.

b. Graduate Programs: i. Residency Programs:

1. “Organ and Tissue Donation for Transplantation.” Lecture to pediatric

residents at The Children’s Hospital of Alabama, Birmingham, Alabama. May 12, 1998.

2. “Transplant/Immunocompromised Patients.” Lecture at the Trauma/Surgical Critical Care Seminar series at The University of Alabama Hospital. March 16, 2001.

3. “Critical Care After Liver Transplantation.” Lecture in the UAB Trauma/Critical Care lecture series for Surgery/Anesthesia House staff. July 27, 2001.

4. “Hepatobiliary/Liver.” Attending advisor for University of Alabama at Birmingham General Surgery Resident’s Basic Science Conference. November 1, 2001.


5. “Organ and Tissue Donation for Transplantation.” Lecture to Morehouse School of Medicine Surgery House staff July 23, 2008.

6. “The Transplant Patient’s Journey.” Atlanta Medical Center, General Surgery Resident Educational Conference, Atlanta Medical Center, Atlanta, Georgia, August 16, 2012.

7. “Organ Donation and Transplantation.” Atlanta Medical Center, General Surgery Resident Educational Conference, Atlanta Medical Center, Atlanta, Georgia, September 9, 2015.

8. “Renal Transplantation.” Emory University, General Surgery Resident Educational Conference, Emory University, Atlanta, Georgia, June 29, 2017.

ii. Master’s and PhD Programs:

1. Course #PHY 750/751 (combined University of Alabama at Birmingham

medical/graduate school elective entitled “Clinical and Molecular Physiology and Medicine: Fundamental Insights into Common Diseases”). “Hepatitis C and Liver Transplantation.” Lecture May 25, 1999, 1 hour.

2. Course #IBS 701 (Integrative Biomedical Sciences II course for first-year University of Alabama at Birmingham Physiology PhD students entitled “Pathophysiology and Pharmacology of Disease,” January-April 2000), 10 hours.

3. Section Head for “Hepatic and Gastrointestinal Physiology and Pathology.”

a. “Digestion and Absorption” – Lecture February 17, 2000. b. “Liver Function and Gallstones” – Lecture February 17, 2000. c. “Peptic Ulcer Disease and Therapy” – Lecture February 18, 2000. d. “Gastrointestinal Neoplasia and Inflammatory Bowel Disease” – Lecture

February 18, 2000. e. “Pancreatitis and Pancreatic Tumors” – Lecture February 21, 2000. f. “Hepatitis, Cirrhosis, and Jaundice” – Lecture February 21, 2000.

c. Other Categories:

1. “GI Physiology/Peptic Ulcer Disease.” Lectures January 21, 1998, 2. January 19, 2000, January 24, 2001 to University of Alabama at Birmingham

Physician/Surgeon Assistant students, 1 hour each = 4 total hours.

3. “Liver Transplantation.” Lectures May 13, 1998, May 19, 1999, May 11, 2000, to University of Alabama at Birmingham Physician/Surgeon Assistant students, 1 hour each = 3 total hours.


4. “Portal Hypertension.” Lectures November 11, 1998, October 29, 1999, October 20, 2000, October 12, 2001 to University of Alabama at Birmingham Physician/Surgeon Assistant students, 1 hour each = 4 total hours.

23. Supervisory Teaching:

a. Other:

1. Jason Schwarz, Summer Research Intern, 2013. Current 3rd year student at

Emory University School of Medicine, Atlanta, Georgia.

2. Sydney Huggins, Summer Research Intern, 2012-2013. Current 2nd year student at Virginia College of Osteopathic Medicine, Spartanburg, South Carolina.

24. Lectureships, Seminar Invitations, and Visiting Professorships: a. National and International

b. Regional

1. “Comparison of Clinical and Molecular Prognostic Factors in Breast Cancer

Patients after a 16-Year Follow-up.” Department of Surgery Grand Rounds, Carraway Methodist Medical Center, Birmingham, Alabama. June 13, 1994.

2. “The Liver Transplant Evaluation Process.” Carraway Methodist Medical Center, Medical Staff Grand Rounds, Birmingham, Alabama. November 25, 1997.

3. “Organ and Tissue Donation for Transplantation.” Lloyd Noland Hospital, Medical Staff Grand Rounds, Birmingham, Alabama. April 27, 1998.

4. “Safe Surgical Therapy for Hepatocellular Carcinoma in Patients with Child’s C Cirrhosis.” Annual Meeting of the Alabama Chapter of the American College of Surgeons. Destin, Florida. May 2001.

5. “Advances in Therapy of Primary Liver Cancer and Cancers Metastatic to the Liver.” Medical Grand Rounds, Medical Center of Central Georgia, Macon, Georgia. September 12, 2007

6. “Precision Trans-arterial Chemoembolization with Drug-eluting Beads for the treatment of Hepatocellular Carcinoma.” Vanderbilt University Division of Liver Transplantation and Hepatobiliary Surgery Grand Rounds, Nashville, Tennessee. January 29, 2009.


7. “Hepatocellular Carcinoma.” Department of Surgery Grand Rounds, Mercer University Memorial Hospital, Savannah, Georgia. February 27, 2014.

8. “Solid Organ Procurement and Transplantation.” Department of Medicine Grand Rounds, Archbold Medical Center, Thomasville, Georgia. May 20, 2014.

9. “Organ and Tissue Donation for Transplantation.” Baptist Medical Center-Montclair, Medical Staff Grand Rounds, Alabama, Birmingham, Alabama. Televised closed circuit to other Baptist Medical Center-affiliated hospitals in Alabama. July 2, 1998.

10. “Organ and Tissue Donation for Transplantation.” Medical Center East Hospital, Medical Staff Grand Rounds, Birmingham, Alabama. January 5, 1999.

11. “Organ and Tissue Donation for Transplantation.” Decatur General Hospital, Medical Staff Grand Rounds, Decatur, Alabama. April 20, 1999.

12. “Organ Donation from Non-Brain Dead Donors.” Brookwood Medical Center, Medical Staff Grand Rounds, Birmingham, Alabama. April 28, 1999.

13. “Organ and Tissue Donation for Transplantation.” Bessemer Carraway Medical Center, Medical Staff Grand Rounds, Bessemer, Alabama. May 25, 1999.

14. “An Update on Organ and Tissue Donation.” Northeast Regional Alabama Medical Center, Medical Staff Grand Rounds, Anniston, Alabama. February 10, 2000.

15. “Organ and Tissue Donation for Transplantation.” St. Clair County Hospital, Medical Staff Grand Rounds, Pell City, Alabama. September 18, 2000.

16. “Organ and Tissue Donation for Transplantation.” East Alabama Medical Center, Medical Staff Grand Rounds, Opelika, Alabama. November 13, 2001.

17. “Organ Donation for Transplantation.” Colbert County Medical Society, Helen Keller Memorial Hospital, Medical Staff Grand Rounds, Florence, Alabama. February 12, 2002.

18. “Organ Donation for Transplantation.” Walker Baptist Medical Center,

Medical Staff Grand Rounds, Jasper, Alabama. June 4, 2002.

19. “Importance of Organ Donation for Transplantation in the Delaware Valley.” Crozer-Chester Medical Center, Medical Staff Grand Rounds, Chester,


Pennsylvania. January 8, 2004.

20. “Anesthetic Considerations in Pediatric Renal Transplantation.” Department of Pediatric Anesthesia Grand Rounds, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania. March 11, 2004.

21. “Treatment of Liver Metastases from Colorectal (and other) Cancer.” Satilla Regional Medical Center, Medical Staff Grand Rounds, Waycross, Georgia. June 14, 2007.

22. “Advances in Therapy of Primary Liver Cancer and Cancers Metastatic to the Liver.” Department of Medicine Grand Rounds, Medical Center of Central Georgia, Macon, Georgia. September 12, 2007.

23. “Precision Trans-arterial Chemoembolization with Drug-eluting Beads for the treatment of Primary and Metastatic Liver Tumors.” Kennestone Hospital Tumor Board, Marietta, Georgia, December 8, 2008.

24. “Precision Trans-arterial Chemoembolization with Drug-eluting Beads for the treatment of Hepatocellular Carcinoma.” Vanderbilt University Division of Liver Transplantation and Hepatobiliary Surgery Grand Rounds, Nashville, Tennessee, January 29, 2009.

25. “Liver and Kidney Transplant Outcomes.” Department of Anesthesia Grand Rounds, Gwinnett Medical Center, Lawrenceville, GA. August 27, 2012.

26. “Organ and Tissue Donation for Transplantation.” Columbus Regional Medical Center, Medical Staff Grand Rounds, Columbus, Georgia. May 11, 2010.

27. “Organ and Tissue Donation for Transplantation.” Redmond Medical Center, Medical Staff Grand Rounds, Rome, Georgia, May 24, 2011.

28. “The Process of Organ and Tissue Transplantation.” Atlanta Medical Center, Department of Anesthesia Educational Conference, Atlanta, Georgia, July 17, 2013.

29. “Hepatocellular Carcinoma.” Mercer University Memorial Hospital, Department of Surgery Grand Rounds. Savannah, Georgia, February 27, 2014.

30. “Solid Organ Procurement and Transplantation.” Archbold Medical Center, Medical Grand Rounds. May 20, 2014.

31. “Results of Solid Organ Transplantation.” Archbold Medical Center, Lunch-n-Learn CME Conference. May 20, 2014.


32. “The Process (and Results) of Organ Procurement and Transplantation.”

Northeast Georgia Regional Medical Center, Physician Education Seminar. Gainesville, Georgia, May 23, 2014.

33. “The Process of Organ and Tissue Transplantation.” Medical Conference, Saint Joseph’s Hospital/Emory Healthcare, Atlanta, Georgia. October 15, 2014.

34. “Solid Organ Donation: Referral Process.” Physician Education Conference, Gwinnett Medical Center, Lawrenceville, GA. November 12, 2014.

35. “The Process (and Importance) of Organ Procurement and Transplantation.”

American Association of Neuroscience Nurses Association, Atlanta Metropolitan Chapter, Atlanta, GA. February 20, 2018.

36. “Organ Donor Management.” Trauma Grand Rounds, Wellstar Atlanta

Medical Center. Atlanta, GA. April 2, 2018.

c. Institutional:

1. “Hepatocellular Carcinoma.” Department of Surgery Grand Rounds, University of Alabama at Birmingham. December 31, 1994.

2. “Organ and Tissue Donation for Transplantation.” The Children’s Hospital of Alabama, Birmingham. Alabama, May 12, 1998.

3. “Anesthetic Considerations in Pediatric Renal Transplantation.” Department of Pediatric Anesthesia Grand Rounds, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania. March 11, 2004.

4. “Early Steroid Withdrawal following Renal Transplantation.” Piedmont Hospital, Transplant Educational Conference. Atlanta, Georgia, February 23, 2006.

5. “Management of Portal Hypertension.” Perry Hospital Staff Meeting, Perry, Georgia. August 8, 2006.

6. “Liver Cancer: Reasons for Hope.” Piedmont Hospital Davies Lecture Series, Atlanta, Georgia. June 28, 2007.

7. “Ethical Issues in Solid Organ Transplantation.” Department of Medicine Grand Rounds, Piedmont Hospital, Atlanta, Georgia. October 1, 2014.

8. “Hepatocellular Carcinoma in 2017.” Emory University Surgical Grand

Rounds, April 20, 2017.


9. “Surgical Management of Hepatocellular Carcinoma.” Emory University

Interventional Radiology Grand Rounds, August 17, 2017.

25. Invitations to National/International, Regional, and Institutional Conferences:

a. National and International

1. “TACE with Doxorubicin-eluting Beads for HCC, with Histologic Evidence of

Efficiency in Transplanted Patients.” International Liver Cancer Association, 2nd Annual Meeting, Satellite Symposium, Chicago, Illinois, September 5, 2008.

2. “HCC Upgrades: Still too generous? No.” The Liver Meeting, American Association for the Study of Liver Diseases. Boston, Massachusetts, October 31, 2009.

3. “Four Year Review of Drug-Eluting-Bead, doxorubicin (DEBDOX) for HCC:

Clinical and Pathological Results and Lessons Learned.” International Hepato-Pancreato-Biliary Association, 9th World Congress, Satellite Symposium, Buenos Aires, Argentina, April 20, 2010.

4. “Liver Transplantation for Primary Hepatic Neuroendocrine Tumors.”

University of Colorado annual conference on “Controversies in Transplantation.” Breckenridge, Colorado. March 6, 2011.

5. “Surgical Approaches to Malignant Biliary Strictures.” The Liver Package® Symposium. Las Vegas, Nevada. September 22, 2011.

6. “Malignant Neoplasms: Alternative Surgical Approaches.” The Liver Package® Symposium. Las Vegas, Nevada. September 23, 2011.

7. “Surgical Approaches to Portal Hypertension.” The Liver Package® Symposium. Las Vegas, Nevada. September 12, 2012.

8. “Pushing the Surgical Boundaries for Hepatic Malignancies.” The Liver Package® Symposium. Las Vegas, Nevada. September 12, 2012.

9. “Improving Outcomes with an Integrated Liver Team Approach for Treating Patients with Liver Cirrhosis.” The 25th International Symposium on Endovascular Therapy, Miami Beach, Florida, January 21, 2013.

b. Regional


1. “Liver Transplantation and Surgery.” The Montgomery Area Chapter of the American Association for Medical Transcription. Birmingham, Alabama. October 10, 1998.

2. “Mechanisms and Treatment of Rejection.” The Transplant Nurses Association, Birmingham, Alabama. June 23, 1999.

3. “Safe Surgical Therapy for Hepatocellular Carcinoma in Patients with Child’s C Cirrhosis.” Annual Meeting of the Alabama Chapter of the American College of Surgeons. Destin, Florida. May 2001.

4. “Liver Transplantation.” Alabama Organ Center: Fall Update on Organ Donation, Huntsville, Alabama. October 29, 2001.

5. “Pediatric Renal Transplantation: Surgical Issues.” Solid Organ Transplant Course, Children’s Hospital of Philadelphia Nursing Staff, Philadelphia, Pennsylvania. October 25, 2004.

6. “The Use and Clinical Impact of Deceased Expanded Donors in Kidney Transplantation.” American Society of Histocompatibility and Immunogenetics 2005 Eastern Regional Education Workshop, Philadelphia, Pennsylvania. May 14, 2005.

7. “Organ Donor Management.” Third Annual Southeastern Critical Care Summit, Emory University, Atlanta, GA, February 8, 2010.

8. “Steroid Withdrawal following Kidney and Liver Transplantation.” Georgia Chapter of the International Transplant Nurses Society, Atlanta, Georgia. June 5, 2006.

9. “Advances in Therapy of Primary Liver Cancer and Cancers Metastatic to the Liver.” Case Managers Society of America-Atlanta Chapter’s Annual Conference, Atlanta, Georgia. October 6, 2007.

10. “Advances in Therapy of Primary Liver Cancer and Cancers Metastatic to the Liver.” Commission for Case Manager Certification, Atlanta, Georgia, March 11, 2008.

11. “Transplantation: Crossing the Bridge.” Organ Donation: Bridging the Gap. Gwinnett Medical Center, Lawrenceville, Georgia, December 11, 2008.

12. “Success in Transplantation.” LifeLink of Georgia conference on “Palliative Care and Donation Symposium.” Atlanta, Georgia. October 16, 2009.

13. “Hepatocellular Carcinoma: Current Role of Liver Transplantation. Is it diminishing?” Georgia Cancer Foundation conference on “Hepatocellular


Carcinoma: A Multidisciplinary Approach.” Atlanta, Georgia. October 24, 2009.

14. “History of Liver Transplantation.” OptumHealth Spotlight Conference on “Liver Disease and Transplantation.” Atlanta, Georgia. October 28, 2011.

15. “Challenges of Hepatocellular Carcinoma – Surgical.” OptumHealth Spotlight Conference on “Liver Disease and Transplantation.” Atlanta, Georgia. October 28, 2011.

16. “Hepatocellular Carcinoma.” Georgia Chapter of the International Transplant Nurses Society, Atlanta, Georgia. April 20, 2013.

c. Institutional

1. “Surgical Management of Hepatocellular Carcinoma.” The University of

Alabama at Birmingham Liver Center CME course, Birmingham, Alabama, October 1, 1999.

2. “Liver Transplantation and other Hepatobiliary Surgery Terminology.” The University of Alabama at Birmingham Medical Records Physician Education Series, Birmingham, Alabama. October 22, 1999.

3. “Hepatocellular Carcinoma in 2007: Surgical Management and Outcomes.” Piedmont Hospital Transplant Services’ Annual Update on Liver and Kidney Disease and Transplantation 2007 course, Braselton, Georgia. March 24, 2007.

4. “Transplantation for Hepatocellular Carcinoma Outside the Milan Criteria.” Piedmont Hospital Annual CME Update: “Update on Liver and Kidney Transplantation: Controversies in Transplantation,” Atlanta, Georgia. October 10, 2009.

5. “Hepatitis C Treatment – An Update.” LifeLink Foundation Medical Advisory

Committee Meeting,” Tampa, Florida. November 4, 2015.

26. Abstract Presentations at National/International, Regional, and Institutional Conferences: a. National and International:

1. Sellers MT*, Beenken S, Blankenship A, Soong S, Urist M, Maddox W.

“Prognostic Significance of Cervical Lymph Node Metastases in Differentiated Thyroid Cancer.” Third International Conference on Head and Neck Cancer, San Francisco, California, July 1992. (oral presentation)


2. Sellers MT*, Grizzle W, Huang P, Peters G, Litinski C, Stockard C, Hubbard W, Wheeler R, Beenken S. “Identification of a 33 kDa Intron-binding Protein Required for Transformation Ability of the p53 Gene in vitro.” Surgical Forum. San Francisco, California, October 1993. (oral presentation)

3. Sellers MT*, Crowe D, Conner M, Maddox W, Beenken S. “Multivariate Analysis of Prognostic Factors in Breast Cancer After 16 Years of Follow-up.” Sixteenth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, November 1993. (poster presentation)

4. Sellers MT*, Grizzle W, Huang P, Peters G, Litinski C, Stockard C, Hubbard W, Wheeler R, Beenken S. “Modulation of TGFα and Leukoplakia by 13-cis Retinoic Acid.” Society of University Surgeons Thirty-sixth Annual University Surgical Residents’ Conference, Jackson, Mississippi, February 1994. (oral presentation)

5. Sellers MT*, Crowe D, Conner M, Maddox W, Beenken S. “Comparison of Clinical and Molecular Prognostic Factors in Breast Cancer Patients After a 16-Year Follow-up.” Forty-seventh Annual Meeting of the Society of Surgical Oncology, Houston, Texas, March 1994. (oral presentation)

6. Sellers MT*, Grizzle W, Huang P, Peters G, Litinski C, Stockard C, Hubbard W, Wheeler R, Beenken S. “Modulation of TGFα and Leukoplakia by 13-cis Retinoic Acid.” Eighty-fifth Annual Meeting of the American Association for Cancer Research, San Francisco, California, April 1994. (oral presentation)

7. Huang P*, Sellers MT, Grizzle W, Beenken S. “Expression of Potential Surrogate Endpoint Biomarkers in Oral Leukoplakia and their Response to 13-cis Retinoic Acid.” Forty-eighth Annual Meeting of the Society of Surgical Oncology, Boston, Massachusetts, March 1995. (poster presentation)

8. Sellers MT*, Singer A, Maller E, Olthoff K, Jacobowski D, Shaked A. “Late Acute Rejection and Progression to Chronic Rejection in Pediatric Liver Recipients.” Sixteenth International Congress of the Transplantation Society, Barcelona, Spain, August 1996. (poster presentation)

9. Sellers MT*, Noorchasm H, Rostami S, Yokoi Y, Yang Z, Barker C, Naji A. “Transient Depletion of B-Lymphocytes Prevents Chronic Cardiac Allograft Rejection.” Twenty-fourth Annual Scientific Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, May 1998. (oral presentation)

10. Bynon JS*, Eckhoff DE, Sellers MT, Benfield M, Kohaut E, Hudson SL, Diethelm A. A Comparison of Adult and Pediatric Renal Transplantation, A Single Center Experience Over 29 Years. Third International Congress on Pediatric Transplantation, July 1998. (poster presentation)


11. Eckhoff DE*, Sellers MT, Contreras J, Benfield M, Kohaut E, Hudson SL, Diethelm AG, Bynon JS. The Evolving Challenges of Pediatric Renal Transplantation. Third International Congress on Pediatric Transplantation, Boston, Massachusetts, July 1998. (poster presentation)

12. Contreras J*, Bilbao G, Krasnykh V, Mikheeva G, Dmitriev I, Belousova N, Eckhoff DE, Sellers MT, Thomas F, Thomas J, Curiel D. Genetically Modified Adenoviral Vector Containing a Heterologous RGD Peptide in the hi Loop of the Fiber Knob Improves Gene Transfer to Vascular Endothelial Cells in Organ Culture. Sixtieth Annual Meeting of The Society of University Surgeons, February 1999. (oral presentation)

13. Ray P*, Sellers MT, Nadler S, Thomas J. BMS-205820 (A Novel NF-Kappa

B Inhibitor) Prolongs Survival of Rat Cardiac Allografts After a Short Course of Cyclosporine. Twenty-fifth Annual Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, May 1999. (oral presentation)

14. Sellers MT*, Hudson SL, Young, CJ, Bynon JS, Eckhoff DE, Gallichio MH, Deierhoi, MH, Diethelm AG, Thompson JA. “Improved Outcomes in Cadaveric Renal Allografts with Pulsatile Preservation.” Twenty-fifth Annual Scientific Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, May 1999. (oral presentation)

15. Smith PD*, Meng G, Sellers MT, Mosteller-Barnum M, Rogers TS, Shaw

GM. Lymphocytes, Not Macrophages, are the Primary Target Cell for HIV-1 in the Intestinal Mucosa. 4th International Workshop on HIV, Cells of Macrophage Lineage, and other Reservoirs, Amsterdam, The Netherlands, December 1999. (oral presentation)

16. Sellers MT*, McGuire BM, Eckhoff DE, Hudson SL, Bynon JS. “Feasibility of Steroid Withdrawal in Liver Transplantation – An Experience with 288 Patients.” First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, Illinois, May 2000. (oral presentation)

17. Singer AL*, Kim HC, Sellers MT, Cuy R, Friedman D, Higuchi N, Dugan N,

Rand EB, Maller E, Olthoff KM, Shaked A. The Use of Plasmapheresis for the Management of Acute Hepatic Failure in the Pediatric Population. First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, Illinois, May 2000. (poster presentation)

18. Singer AL*, Sellers MT, Mailer E, Rand E, Higuchi N, Zamir G, Markmann J,

Shaked A, Olthoff K. “Variables Affecting Graft Function and Quality of Life 1


vs. >5 Years After Pediatric Liver Transplantation.” First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, Illinois, May 2000. (poster presentation)

19. Sellers MT*, Eckhoff DE, Bynon JS, Heslin MJ. “Laparoscopic Radiofrequency Ablation for Hepatocellular Carcinoma in Advanced Cirrhosis.” International Hepato-Pancreato-Biliary Association Fourth World Congress, Brisbane, Queensland, Australia, May 2000. (oral presentation)

20. Smythies LE*, Barnum MM, Sellers MT, Smith PD. “Resident Intestinal

Macrophages Exhibit Unique Phenotype and Down-regulate Inflammatory Cytokine Production.” Keystone Symposium – Macrophage Activation and Deactivation, Keystone, Colorado, January 2001. (oral presentation)

21. Sellers MT*, Haustein SV, McGuire BM, Eckhoff DE, Jones CJ, Hudson SL, Bynon JS. “Incidence of and Multivariate Analysis of Risk Factors for Chronic Hepatic Allograft Rejection.” International Liver Transplant Society, Berlin, Germany, July 2001. (oral presentation)

22. Sellers MT*, Haustein SV, McGuire BM, Eckhoff DE, Jones CJ, Hudson SL, Bynon JS. “Impact of Recipient Noncompliance on Chronic Rejection of Liver Allografts.” Transplant Immunosuppression 2001: The Compleat Care of the Transplant Recipient, Minneapolis, Minnesota, October 2001. (oral presentation)

23. Haustein SV*, McGuire BM, Eckhoff DE, Hudson SL, Bynon JS, Sellers MT. “Impact of Noncompliance and Donor/Recipient Race Matching on Chronic Liver Rejection.” Second International Congress on Immunosuppression, San Diego, California, December 2001. (poster presentation)

24. Haustein SV*, Sellers MT. “Characteristics Associated with (Un)Willingness to be an Organ Donor: Results of a Public Survey.” American Transplant Congress 2002, Washington, D.C., April 2002. (poster presentation)

25. Sellers MT*, McGuire BM, Haustein SV, Bynon JS, Hunt SL, Eckhoff DE. “Long-term Follow-up of Daclizumab Induction in Liver Transplant Recipients.” American Transplant Congress 2002, Washington, D.C., May 2002. (oral presentation)

26. Sellers MT*, Velidedeoglu E, Bloom RD, Grossman RA, Markmann JW, Naji A, Frank AM, Kass AB, Nathan HM, Hasz RD, Abrams JD, Markmann JF. “Outcome of Expanded Criteria Donor Kidneys Transplanted at a Single Center – Resource Utilization and Long-term Function.” American Transplant Congress 2003, Washington, D.C., May 2003. (poster presentation)


27. Bloom RD*, Sayer G, Mange K, Doyle A, Goral S, Grossman RA, Naji A, Markmann J, Sellers M, Reddy R. Long-term Outcome of Hepatitis C Virus (HCV)-infected Kidney Recipients without Pre-transplant Diabetes. American Transplant Congress 2003, Washington, D.C., May 2003. (poster presentation)

28. Bloom RD*, Sayer GT, Constantinescu S, Fa K, Goral S, Doyle AM, Naji A, Markmann JF, Grossman RA, Sellers MT. Increased mortality in hepatitis C virus (HCV)+ kidney recipients is associated with pre-existing diabetes (DM). American Transplant Congress 2004, Boston, Massachusetts, May 2004. (poster presentation)

29. Abt P*, Frank A, Stephenson GR, Sellers MT. “Factors associated with survival of non-heart-beating donor kidneys.” American Transplant Congress 2004, Boston, Massachusetts, May 2004. (poster presentation)

30. Frank AM*, Deng S, Thambi-Pillai T, Velededeoglu E, Desai NM, Huang X,

Lian MM, Mohiuddin MM, Bae YS, Stephenson GR, Abt PL, Sellers MT, Barker CF, Naji A, Markmann JF. Comparison of whole organ pancreas and isolated islet transplantation for type 1 diabetes. American Transplant Congress 2004, Boston, Massachusetts, May 2004. (oral presentation)

31. Mange KC*, Doyle A, Goral S, Sellers M, Bloom R. Impact on Clinical

Studies of the Choice of Equations to Estimate Renal Function. American Transplant Congress 2004, Boston, Massachusetts, May 2004. (oral presentation)

32. Goral S*, Bloom R, Doyle A, Grossman R, Naji, A, Sellers M, Markmann J,

Kamoun M. Managing a Large Kidney Transplant Waiting List: Impact of sensitization to HLA Antigens and Patient’s Listing Status on Waiting Time. American Transplant Congress 2005, Seattle, Washington, May 2005. (poster presentation)

33. Goral S*, Eren P, Bloom R, Doyle A, Grossman R, Israni A, Naji, A, Sellers M, Markmann J, Kearns J, Kamoun M. Impact of Sensitization to HLA Class I and Class II Antigens (Ag) on Receiving a 2nd Kidney Transplant (Tx) after a Failed Graft: Report from a Transplant Center Using a Stringent HLA Crossmatching (XM) Strategy. American Transplant Congress 2005, Seattle, Washington, May 2005. (poster presentation)

34. Frank AM*, Markmann J, Yeh H, Porrett PM, Huang XL, Velidedeoglu E, Mohiuddin MM, Deng S, Sellers MT, Naji A, Shaked A, Markmann JF. Kidney transplantation in type 1 diabetics: an analysis of 15 years of OPTN data. American Transplant Congress 2005, Seattle, Washington, May 2005. (oral presentation)


35. Eren P*, Goral S, Bloom R, Doyle A, Grossman R, Israni A, Naji A, Sellers M, Markmann J, Kearns J, Kamoun M. Impact of sensitization to HLA class I and class II antigens on receiving a second kidney transplant after a failed graft. XLII Congress of the European Renal Association, Istanbul, Turkey, June 2005. (oral presentation)

36. Yeh H*, Abrams J, Porrett P, Sellers M, Naji A, Shaked A, Bortecen K, Hasz R, Markmann J. “Expedited Cross-matching for Marginal Kidneys Decreases Cold Ischemia Time and Improves Function.” 2006 World Transplant Congress, Boston, Massachusetts, July 2006. (poster presentation)

37. Johnson M*, Tan M, Pollinger H, Sellers M, Cross R, Scouller T, Logen-Bossie A, Williams S, Wolf J, Whelchel J, Zayas C. “Ureteral Stents in Renal Transplantation: BK Friend or Foe?” American Transplant Congress 2009, Boston, Massachusetts, June 2009. (poster presentation)

38. Tan M*, Cross R, Wolfe J, Pollinger H, Johnson M, Sellers M, Whelchel J,

Zayas C. “IVIG Therapy in Positive Crossmatch Kidney Transplants is Associated with a Decreased Incidence of Polyomavirus Infection.” American Transplant Congress 2009, Boston, Massachusetts, June 2009. (poster presentation)

39. Sellers M*, Kegley K, Shrestha R, Johnson M, Bruno C, Tan M, Pollinger H,

Citron S. “Precision transarterial chemoembolization for hepatocellular carcinoma: histologic efficacy in transplanted patients and safety in advanced cirrhotics.” American Transplant Congress 2009, Boston, Massachusetts, June 2009. (poster presentation)

40. Pollinger H*, Tan M, Wolf J, Johnson M, Sellers M, Cross R, Bray R, Gebel H, Zayas C, Whelchel J. “Positive Crossmatch Kidney Transplantation in a Non-academic Transplant Program: Is It Feasible?” American Transplant Congress 2009, Boston, Massachusetts, June 2009. (poster presentation)

41. Johnson M*, Sellers M, Tan M, Pollinger H, Cross R, Sutton P, Berry C,

Panjala C, Stein L, Bruno C, Shrestha R. “Routine Use of Abdominal CT Scans after Biliary Leaks in Liver Transplant Recipients: Is it Clinically or Cost Effective? American Transplant Congress 2011, Philadelphia, Pennsylvania, May 2011. (poster presentation)

42. Panjala C*, Stein L, Bruno C, Tan M, Pollinger H, Sellers M, Johnson M,

Shrestha R. Utility of Pre-LT Locoregional Therapy for HCC in UNOS Regions Where Waiting Time for LT Is Historically Shorter. American Transplant Congress 2011, Philadelphia, Pennsylvania, May 2011. (oral presentation)

43. Stein L*, Panjala C, Kegley K, Sellers M, Tan, Pollinger H, Bruno C,


Shrestha R, Johnson M. Impact of Early Sirolimus Use on Fibrosis Progression and Graft Survival in HCV Liver Allograft Recipients: A Single Center Experience. American Transplant Congress 2011, Philadelphia, Pennsylvania, May 2011. (poster presentation)

44. Johnson M*, Sellers M, Tan M, Pollinger H, Cross R, Sutton P, Berry C, Panjala C, Stein L, Bruno C, Shrestha R. Routine Use of Abdominal CT Scans After Biliary Leaks in Liver Transplant Recipients: Is it Clinically or Cost Effective? American Transplant Congress 2011, Philadelphia, Pennsylvania, May 2011. (poster presentation)

45. Sellers MT*, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Tan M, Arepally A, Citron SJ. “Multivariate analysis of prognostic factors following chemoembolization with doxorubicin-eluting beads for hepatocellular carcinoma.” Society of Interventional Radiology, 37th Annual Scientific Meeting, San Francisco, California, March 2012. (oral presentation)

46. Sellers MT*, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Tan M, Arepally A, Citron SJ. “Comparison Of Doxorubicin-Eluting Bead Transarterial Chemoembolization And Resection For Early Hepatocellular Carcinoma.” International Liver Cancer Association, 2012 Annual Conference, Berlin, Germany, September 15, 2012. (poster presentation)

47. Sellers MT*, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Tan M, Arepally A, Citron SJ. “Multivariate analysis of prognostic factors following chemoembolization with doxorubicin-eluting beads for hepatocellular carcinoma.” International Liver Cancer Association, 2012 Annual Conference, Berlin, Germany, September 15, 2012. (poster presentation)

48. Johnson MW*, Sellers MT, Carew N, Rubin R, Galambos M, Shrestha R. “Impact of a new adult liver transplant program on transplant and procurement volumes in an organ procurement organization.” Health Resources and Services Administration, Organ Donation and Transplantation Alliance, 7th National Learning Congress, Grapevine, Texas, October 4-5, 2012. (poster presentation)

49. Sellers MT*, Alperin M. “Multivariate analysis of factors associated with willingness to be an organ donor - a basis for organ donation advocacy/awareness.” The 141st American Public Health Association Annual Meeting, Boston, Massachusetts, November 4, 2013. (poster presentation)

50. Mulloy, M*, Cross R, Tan M, Sellers M, Johnson M, Ommert T, D'Annunzio

S, Pollinger H. “Protocol-based Reduction in Narcotic Use and Length of Stay Following Robotic Live Donor Nephrectomy.” World Transplant


Congress, San Francisco, California, July 2014. (poster presentation)

51. Sellers MT*, Lee R, Turgeon N, Pearson T, Davis J, Lilly K, McDonald B, Langley L. “Liver-only Deceased Donors – Are they Worth Pursuing?” ASTS 17th Annual State of the Art Winter Symposium, Miami, Florida, January 27, 2017. (poster presentation)

52. Sellers MT*, Alperin M. “Multivariate Analysis of Factors Predicting

Willingness to be an Organ Donor – Targets for Intervention.” Annual State of the Art Winter Symposium, Miami, Florida. January 27, 2017. (poster presentation)

53. Sellers M*, Lee R, Owens Z, Turgeon N, Pearson T, Davis J, Lilly K,

McDonald B, Langley L. “Excellent Outcomes following Transplantation of Livers from Over 400 Single-Organ Donors.” Association of Organ Procurement Organization's 2017 Annual Meeting, Orlando, Florida, June 21, 2017. (poster presentation; recognized as 3rd best abstract)

54. Jonsson A*, Patel LY, Flink BJ, Davis Jr. SS, Lin E, Sellers MT. "Robotic

common bile duct resection with roux-en-Y hepaticojejunostomy for Anomalous Pancreaticobiliary Junction". American College of Surgeons Clinical Congress, San Diego, California, October 23, 2017. (video presentation)

55. Sellers MT*, McGinnis HS, Alperin M, Sweeney JF, Dodson TF. Deterrents

to Organ Donation – A Multivariate Analysis of 766 Survey Respondents. 129th Annual Meeting of the Southern Surgical Association, Hot Springs, Virginia, December 4, 2017. (oral presentation)

56. Sellers MT*, Lawrence P, Marshman D, Lilly K, Langley L. “Kidney Yield

from End-stage Renal Disease (ESRD) Donors -- In theory, there is no difference between theory and practice; in practice, there is.” 2018 AOPO Annual Meeting, Washington, DC, June 18, 2018 (scheduled). (poster presentation)

57. Sellers M*, Lawrence P, Marshman D, Lilly K, Davis J, Langley L.

“Outcomes from Livers Transplanted from Deceased Donors with End-Stage Renal Disease.” 27th International Congress of The Transplantation Society. Madrid, Spain, July 3, 2018 (scheduled). (oral presentation)

58. Lehr L*, Davis J, Sellers M, Lawrence P. “A Systems-Based Approach to

Increasing Organs Transplanted: One Organ Procurement Organization’s experience.” 27th International Congress of The Transplantation Society. Madrid, Spain, July 4, 2018 (scheduled). (oral presentation)

59. Bell RD*, Howard B, Lawrence P, Lilly K, Sellers M, Davis J. “Success of a


‘Multicultural Donation Education Program’ to Increase African-American Organ Donation in a Donor Service area with a High African-American Population.” 27th International Congress of The Transplantation Society. Madrid, Spain, July 4, 2018 (scheduled). (oral presentation)

60. McDonald B, Lawrence P*, Sellers M, Wade S, Davis J. “The Great

Recession and the Importance of Donation After Circulatory Determination of Death (DCDD).” 27th International Congress of The Transplantation Society. Madrid, Spain, July 2, 2018 (scheduled). (poster presentation)

b. Regional:

1. Sellers MT*, Crowe D, Conner M, Maddox W, Beenken S. “Comparison of

Clinical and Molecular Prognostic Factors in Breast Cancer Patients after a 16-Year Follow-up.” Annual Meeting of the Alabama Chapter of the American College of Surgeons. Point Clear, Alabama, May 1994. (oral presentation)

2. Sellers MT*, Beenken S, Blankenship A, Soong S, Urist M, and Maddox W. “Prognostic Significance of Cervical Lymph Node Metastases in Differentiated Thyroid Cancer.” Eighty-eighth Annual Scientific Assembly of the Southern Medical Association. Orlando, Florida, November 1994. (oral presentation)

3. Sellers MT*, Crowe D, Conner M, Maddox W, Beenken S. “Multivariate Analysis of Clinical and Molecular Prognostic Factors in Breast Cancer: A 16-Year Follow-up.” Eighty-eighth Annual Scientific Assembly of the Southern Medical Association. Orlando, Florida, November 1994. (oral presentation; award for best oral presentation, First Place, Surgery Section)

c. Local:

1. Sellers MT*, Perez S, Blair C, Little L, Chandler P, Sharma N, Jones J, Sarmiento J. Reducing 30-day Readmissions after HPB Surgery. Emory Healthcare’s 10th Annual Quality Conference, Atlanta, Georgia, June 1, 2017. (Received award for Most Outstanding Quality Improvement Intervention.)

27. Research Focus:

1. Identifying ways to increase total number of organs available for

transplantation by optimizing organ donation awareness and organ donor management.


2. Improving efficiency of care delivery and outcomes for patients with

hepatocellular carcinoma in the setting of chronic liver disease.

3. QAPI initiatives and improving healthcare outcomes, especially following hepato-pancreato-biliary surgery.

28. Grant Support: a. Previous Support:

1. Principal investigator.

Analysis of the Effect of Oral Administration of 13-cis Retinoic Acid on Proto-oncogene Amplification in Patients with Leukoplakia. Southern Medical Association. $2500, Grant,1992.

2. Principal investigator. Effect of Interferon-alpha on the Development of Experimental Metastases in a Murine Model. Southern Medical Association. $2500, Grant,1993.

3. Principal Investigator. National Cancer Institute, National Institutes of Health. A Phase IIb Randomized, Double-blind, Placebo-controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients with a History of Non-melanoma Skin Cancer. $1,465,072, Contract, # N01-CN-15136, 2001-2002.

4. University of Pennsylvania Principal Investigator. Novartis International AG. A one-year, multicenter, double blinded, double dummy, randomized study to evaluate the efficacy and safety of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids in de novo adult renal transplant recipients. $123,990, Grant, 2003.

5. University of Pennsylvania Principal Investigator. Novartis International AG. A prospective, multi-center, open-label, randomized study of the safety, tolerability and efficacy of Certican® (RAD001) with Simulect®, corticosteroids and lower levels versus higher levels of tacrolimus in de novo renal transplant recipients. $57,852, Grant, 2003.

6. University of Pennsylvania Principal Investigator.


Fugisawa Pharmaceutical. A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf® (tacrolimus)/MMF, modified release (MR) tacrolimus/MMF and Neoral® (cyclosporine)/MMF in de novo kidney transplant recipients. Dollar amount unavailable, Grant, 2003.

7. University of Pennsylvania co-investigator Wyeth Pharmaceuticals. A randomized open-label study to compare the safety and efficacy of two different sirolimus regimens with a tacrolimus + mycophenolate mofetil regimen in de novo renal allograft recipients. Dollar amount unavailable, Grant, 2003.

8. University of Pennsylvania co-investigator Wyeth Pharmaceuticals. A randomized study comparing tacrolimus-MMF-prednisone to rapa-MMF-prednisone for patients with established chronic allograft injury. Dollar amount unavailable, Grant, 2003.

9. University of Pennsylvania Principal Investigator. Novartis International AG. A 12-month open-label, multicenter, randomized study to compare the incidence of new onset diabetes mellitus and glucose metabolism in patients receiving Neoral® with C-2 monitoring versus tacrolimus after de novo kidney transplantation. Dollar amount unavailable, Grant, 2003.

10. University of Pennsylvania principal investigator Wyeth Pharmaceuticals. A prospective, randomized trial comparing a sirolimus-based maintenance immunosuppressive regimen to a tacrolimus-based regimen in transplant recipients of expanded criteria kidneys. $160,000, Grant 2005-2006.

11. Piedmont Atlanta Hospital principal investigator. A phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with trans-arterial chemoembolization (TACE) performed with DC Bead and doxorubicin for intermediate stage hepatocellular carcinoma (SPACE). Bayer Healthcare Pharmaceuticals., Dollar amount unavailable, Grant 2009-2010.

12. Piedmont Atlanta Hospital principal investigator. A phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation (STORM). Bayer Healthcare Pharmaceuticals.


Dollar amount unavailable, Grant 2009-2010.

13. Piedmont Atlanta Hospital principal investigator. A phase III randomized, placebo-controlled, double-blind trial of sorafenib plus erlotinib versus sorafenib plus placebo as first line systemic treatment for hepatocellular carcinoma (SEARCH). Bayer Healthcare Pharmaceuticals. Dollar amount unavailable, Grant 2009-2010.

14. Piedmont Atlanta Hospital principal investigator. Refametinib (BAY 86-9766) monotherapy or in combination with sorafenib in RAS-mutant HCC, Bayer Healthcare Pharmaceuticals. Dollar amount unavailable, Grant 2013-2015.

29. Bibliography:

a. Published and Accepted Research Articles (clinical, basic science, other)

in Refereed Journals:

1. Sellers MT, Beenken S, Blankenship A, Soong S, Urist M, and Maddox W. Prognostic Significance of Cervical Lymph Node Metastases in Differentiated Thyroid Cancer. American Journal of Surgery, 1992. 164:578-581.

2. Sellers MT, Kakar R, Ray R, Beenken S. Identification of a 33 kDa Intron-4 Binding Protein Required for Transformation Ability of the p53 Gene in vitro. Surgical Forum, 1993. 44:462-464.

3. Beenken S, Huang P, Sellers MT, Peters G, Listinsky C, Stockard C, Hubbard W, Wheeler R., and Grizzle W. Retinoid Modulation of Biomarkers in Oral Leukoplakia/Dysplasia. Journal of Cellular Biochemistry, 1994. 19:270-277.

4. Weber M, Ketchum RJ, Sellers MT, Aradhye S, Deng S, Grossman R, Shaw L, Naji A, Barker C, Brayman KL. Single Center Analysis of Mycophenolate Mofetil and Neoral/Prednisone Therapy for Prophylaxis of Rejection in African-American and Caucasian Transplant Recipients. Transplantation Proceedings, 1997. 29:338-339.

5. Sellers MT, Singer A, Maller E, Olthoff K, Jacobowski D, Shaked A. Incidence of Late Acute Rejection and Progression to Chronic Rejection in Pediatric Liver Recipients. Transplantation Proceedings, 1997. 29:428-429.

6. Shaked A, Olthoff K, Sellers MT, Chen XD, Gelman A. Tolerance to a Second Donor-matched Allograft Following Local Immune Modulation Using Transfer of Sequence Encoding CTLA-4Ig. Transplantation Proceedings, 1997. 29:1026.


7. Kerby J, Rue L, Blair H, Hudson SL, Sellers MT, Diethelm AG. Operative Treatment of Tertiary Hyperparathyroidism - A Single-Center Experience. Annals of Surgery, 1998. 227:878-886.

8. Eckhoff DE, McGuire BM, Young CJ, Sellers MT, Frenette L, Hudson Sl, Contreras J, Bynon S. Race: A Critical Factor in Organ Donation, Patient Referral and Selection, and Orthotopic Liver Transplantation? Liver Transplantation and Surgery, 1998. 4:499-505.

9. Beenken SW, Sellers MT, Huang P, Peters G, Krontiras H, Dixon P, Stockard C, Listinsky C, Grizzle WE. Transforming Growth Factor α (TGF-α) Expression in Dysplastic Oral Leukoplakia: Modulation by 13-cis Retinoic Acid. Head and Neck, 1999. 21:566-573.

10. Abrams G, Rose K, Fallon MB, McGuire BM, Bloomer JR, van Leeuwen DJ, Tutton T, Sellers MT, Eckhoff DE, Bynon JS. Hepatopulmonary Syndrome and Venous Emboli Causing Intracerebral Hemorrhages After Liver Transplantation: A Case Report. Transplantation, 1999. 68:1809-1811.

11. Beenken SW, Roye D, Weiss H, Sellers MT, Urist M, Diethelm A, Goepfert H. Extent of Surgery for Intermediate Risk Well-differentiated Thyroid Cancer. American Journal of Surgery, 2000. 179:51-56.

12. Eckhoff DE, Blackard WG, Sellers MT, McGuire BM, Bynon JS, Baron T. Role of ERCP in asymptomatic orthotopic liver transplant patients with abnormal liver enzymes. American Journal of Gastroenterology, 2000. 95:141-144.

13. Eckhoff DE, McGuire BM, Sellers MT, Contreras J, Frenette L, Hudson S, Bynon JS. Impact of managed care on liver transplantation: a single center experience with 500 liver transplants. Southern Medical Journal, 2000. 93:392-396.

14. Eckhoff DE, McGuire BM, Sellers MT, Contreras J, Frenette L, Hudson SL, Ingram C, Bynon S. The Safety and Efficacy of a Two-Dose Daclizumab (Zenapax) Induction Therapy in Liver Transplant Patients. Transplantation, 2000. 69:1867-1872.

15. Smith PD, Meng G, Sellers MT, Rogers TS, Shaw GM. Biological Parameters of HIV-1 Infection in Primary Intestinal Lymphocytes and Macrophages. Journal of Leukocyte Biology, 2000. 68:360-365.

16. Meng G, Sellers MT, Mosteller-Barnum M, Rogers TS, Shaw GM, Smith PD. Intestinal Lymphocytes, Not Macrophages, Express CCR5 and CXCR4 and are the Primary Target Cell for HIV-1 in the Mucosa. Journal of Infectious Diseases, 2000. 182:785-791.


17. Sellers MT, Gallichio MH, Hudson SL, Young, CJ, Bynon JS, Eckhoff DE, Deierhoi, MH, Diethelm AG, Thompson JA. Improved Outcomes in Cadaveric Renal Allografts with Pulsatile Preservation. Clinical Transplantation, 2000. 14:543-549.

18. Eckhoff DE, Frenette L, Sellers MT, McGuire B, Contreras JL, Bynon JS, McGiffin DC. Combined Cardiac Surgery and Liver Transplantation. Liver Transplantation, 2001. 7:60-61.

19. Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI. Molecular Biomarkers for Breast Cancer Prognosis: Co-expression of c-erbB-2 and p53. Annals of Surgery, 2001. 233:630-638.

20. Sellers MT, Deierhoi MH, Curtis JJ, Gaston RS, Julian BA, Lanier DC, Diethelm AG. Tolerance in Renal Transplantation After Allogeneic Bone Marrow Transplantation – Six-Year Follow-Up. Transplantation, 2001. 71:1681-1683.

21. Smith PD, Smythies LE, Mosteller-Barnum M, Sibley DA, Russell MW, Merger M, Sellers MT, Shimada T, Graham MF, Kubagawa H. Intestinal Macrophages Lack CD14 and CD89 and Consequently are Down-regulated for LPS- and IgA-mediated Activities. Journal of Immunology, 2001. 167:2651-2656.

22. Medina-Franco H, Sellers MT, Eckhoff DE, Bynon JS, Urist MM, Heslin MJ. Multimodality Treatment for Patients with Hepatocellular Carcinoma: Analysis of Prognostic Factors in a Single Western Institution Series. Journal of Gastrointestinal Surgery, 2001. 5:638-645.

23. Meng G, Wei X, Wu X, Sellers MT, Decker JM, Moldoveanu Z, Orenstein JM, Graham MF, Kappes JC, Mestecky J, Shaw GM, Smith PD. Primary Intestinal Epithelial Cells Selectively Transfer R5 HIV-1. Nature Medicine, 2002. 8:150-156.

24. Alcocer F, Salazar-Gonzalez JF, Jordan WD, Sellers MT, Eckhoff DE, Whitley D. Quercetin Inhibits Human Vascular Smooth Muscle Cells Proliferation and Migration. A novel action of flavonoids. Surgery, 2002. 131:198-204.

25. Sellers MT, Haustein SV, McGuire BM, Jones C, Bynon JS, Diethelm AG, Eckhoff DE. Use of Preserved Vascular Homografts in Liver Transplantation: Hepatic Artery Aneurysms and Other Complications. American Journal of Transplantation, 2002. 2:471-475.


26. Haustein SV, McGuire BM, Eckhoff DE, Hudson SL, Bynon JS, Sellers MT. Impact of Noncompliance and Donor/Recipient Race Matching on Chronic Liver Rejection. Transplantation Proceedings, 2002. 34:1497-1498.

27. van Leeuwen DJ, Sood G, Ferrante D, Lazenby AJ, Sellers MT. A 38-year old African-American Female with an Unusually Rapid Progression of Primary Biliary Cirrhosis. Seminars in Liver Disease, 2002. 22:395-406.

28. Contreras JL, Eckstein C, Smyth CA, Sellers MT, Vilatoba M, Bilbao G, Rahemtulla FG, Young CJ, Thompson JA, Chaudry IH, Eckhoff DE. Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes, 2003. 52:2935-2942.

29. Arch-Ferrer JE, Smith JK, Bynon S, Eckhoff DE, Sellers MT, Bland KI, Heslin MJ. Radiofrequency ablation in cirrhotic patients with hepatocellular carcinoma. American Surgeon, 2003. 69:1067-1071.

30. Haustein SV, Sellers MT. Factors associated with (un)willingness to be an organ donor: importance of public exposure and knowledge. Clinical Transplantation, 2004. 18:193-200.

31. Frank A, Doyle A, Sellers MT. Paired-kidney transplantation between septuagenarian donor and recipient despite unfavorable biopsy and pump data. Transplantation, 2004. 78:785-786.

32. Sellers MT, McGuire BM, Haustein SV, Bynon JS, Hunt SL, Eckhoff DE. Two-dose daclizumab induction therapy in 209 liver transplants – a single center analysis. Transplantation, 2004. 78:1212-1217.

33. Frank A, Deng S, Huang X, Velidedeoglu E, Bae YS, Liu C, Abt P, Stephenson R, Mohuiddin M, Thambipillai T, Markmann E, Palanjian M, Sellers M, Naji A, Barker CF, Markmann JF. Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Annals of Surgery, 2004. 240:631-643.

34. Sellers MT, Velidedeoglu E, Bloom RD, Grossman RA, Markmann JW, Naji A, Frank AM, Kass AB, Nathan HM, Hasz RD, Abrams JD, Markmann JF. Expanded criteria donor kidneys: a single center clinical and short-term financial analysis – cause for concern in retransplantation. Transplantation, 2004. 78:1670-1675.

35. Smythies LE, Sellers MT, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. Journal of Clinical Investigation, 2005. 115:66-75.


36. Greco JA, Baluarte JH, Meyers KEC, Sellers MT, Suchi M, Biegel JA, Kaplan BS. Chromophobe renal cell carcinoma in a pediatric living-related kidney transplant recipient. American Journal of Kidney Diseases, 2005. 45:e105-108.

37. Canter RJ, Abt PL, Litzky LA, Frank A, Abt AB, Sellers M, Markmann JF, Olthoff KM, Naji A, Shaked A. Successful Liver, Kidney, and Pancreas Transplantation from a Donor with Cerebral Emboli from a Left Atrial Myxoma. Transplantation Proceedings, 2005. 37:4334-4336.

38. Smythies LE, Maheshwari A, Clements R, Eckhoff D, Novak L, Mosteller-Barnum M, Sellers MT, Smith PD. Mucosal TGF-β and IL-8 recruit Blood Monocytes to the Intestinal Mucosa: Evidence for Epithelial and Myeloid Cell Cross-talk. Journal of Leukocyte Biology, 2006. 30:492-499.

39. Perveze Z, Johnson MW, Rubin RA, Sellers M, Zayas C, Jones JL, Cross R, Thomas K, Butler B, Shrestha R. Terbinafine-induced Hepatic Failure Requiring Liver Transplantation. Liver Transplantation, 2007. 13:162-164.

40. Saifee S, Joelson D, Braude J, Shrestha R, Johnson M, Sellers M, Galambos MR, Rubin RA. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clinical Gastroenterology and Hepatology, 2008. 6:1167-1169.

41. Connor K, Rubin RA, Shrestha R, Johnson M, Sellers M, Butler B. ABO incompatible liver transplantation as a bridge to treat HELLP syndrome. Gastroenterology Research and Practice 2009:713937. Epub 2009 Sep 28. PubMed ID: 19794830.

42. Kegley KM. Sellers M. Ferber MJ. Johnson MW. Joelson DW. Shrestha R. Fulminant Wilson's disease requiring liver transplantation in one monozygotic twin despite identical genetic mutation. American Journal of Transplantation, 2010. 10(5):1325-9.

43. Namur J, Citron SJ, Sellers MT, Dupuis MH, Wassef M, Manfait M, Laurent A. Embolization of hepatocellular carcinoma with drug eluting beads: analysis of doxorubicin concentration and distribution in patient liver explant. Journal of Hepatology, 2011. 55:1332-1338.

44. Sellers MT, Huggins S, Kegley K, Pollinger HS, Shrestha R, Johnson MW, Tan M, Arepally A, Citron SJ. Multivariate Analysis of Prognostic Factors for Survival following Transarterial Chemoembolization using Doxorubicin-eluting Beads (DEB-DOX) in Patients with Hepatocellular Carcinoma (HCC). Journal of Vascular and Interventional Radiology, 2013. 24:647-654.


45. Naugler WE, Alsina AE, Frenette CT, Rossaro L, Sellers MT. Building the Multidisciplinary Team for Management of Patients with Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2015. 13: 827-835. DOI: 10.1016/j.cgh.2014.03.038)

46. Martin RCG II, Kwon D, Sricharan C, Sellers M, Kotz E, Scoggins C, McMasters KM, Watkins K. Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma with Irreversible Electroporation: Safety and Efficacy. Annals of Surgery, 2015. 262: 486-494. DOI: 10.1097/SLA.0000000000001441.

47. Sellers MT. (Invited Commentary) Paying it Forward: Live Kidney Donation

now to (POSSIBLY) Benefit a Long-term Future Recipient. Transplantation, 2017. 101: 1965-1966. DOI: 10.1097/TP.0000000000001782.

48. Sellers MT, McGinnis HS, Alperin M, Sweeney JF, Dodson TF. Deterrents to

Organ Donation – A Multivariate Analysis of 766 Survey Respondents. Journal of the American College of Surgeons, 2018. 226: 414-422. DOI: 10.1016/j.jamcollsurg.2017.12.029.

b. Book Chapters:

1. O’Brien MA, Sellers MT. Transplantation Surgery. In: Phippen ML, Wells MP, eds. Patient Care During Operative and Invasive Procedures. Philadelphia: Saunders, 2000: 379-403.

2. Sellers MT. Segment-oriented Liver Resection. In: Skandalakis LJ, Skandalakis JE, Skandalakis PN, eds. Surgical Anatomy and Technique. New York: Springer, 2014: 550-563.

3. Pollinger HS, Sellers MT. Laparoscopic Resection of the Pancreas. In: Skandalakis LJ, Skandalakis JE, Skandalakis PN, eds. Surgical Anatomy and Technique: A Pocket Manual. New York: Springer, 2014: 390-395.

4. Sellers MT, Russell M. Liver. In: Skandalakis LJ, Skandalakis JE, Skandalakis PN,

eds. Surgical Anatomy and Technique. New York: Springer (submitted).

c. Published Abstracts:

1. Sellers MT, Beenken S, Blankenship A, Soong S, Urist M, Maddox W. Differentiated Thyroid Cancer: An Analysis of Prognostic Factors. Proceedings of the Third International Conference on Head and Neck Cancer, July 1992.


2. Sellers MT, Crowe D, Conner M, Maddox W, Beenken S. Multivariate

Analysis of Prognostic Factors in Breast Cancer After 16 Years of Follow-up. Breast Cancer Research and Treatment 27: 139, 1993.

3. Sellers MT, Grizzle W, Huang P, Peters G, Litinski C, Stockard C, Hubbard W, Wheeler R, Beenken S. Modulation of TGF-α and Leukoplakia by 13-cis Retinoic Acid. Proceedings of the Eighty-fifth Annual Meeting of the American Association for Cancer Research 35: 621, 1994.

4. Huang P, Grizzle W, Sellers MT, et al TGF-α, EGFR, and HER-2/neu Expression in Oral Leukoplakia and Response to 13-cis Retinoic Acid. Proceedings of the Seventy-sixth Annual Meeting of the American Radium Society.

5. Crowe D, Conner M, Sellers MT, Beenken S, Soong S, Urist M, Maddox W, Shultz J. Prognostic Factors in Breast Carcinoma: Analysis of Pathologic and Molecular Factors with 16-Year Follow-up. Journal of Tumor Marker Oncology 9: 76, 1994.

6. Huang P, Sellers MT, Soong S, Beenken S. Inter-Institutional Comparison of Prognostic Factors and Surgical Results in Patients with Differentiated Thyroid Cancer. Proceedings of the Forty-eighth Annual Meeting of the Society of Surgical Oncology, March 1995.

7. Huang P, Sellers MT, Grizzle W, Beenken S. Expression of Potential Surrogate End Point Biomarkers in Oral Leukoplakia and Their Response to 13-cis Retinoic Acid. Proceedings of the Forty-eighth Annual Meeting of the Society of Surgical Oncology, March 1995.

8. Listinsky C, Huang P, Sellers MT, Wheeler R. Grizzle W, Beenken S. p53 Over-Expression in Patients with Dysplastic Oral Leukoplakia: Lack of Response to Treatment with 13-cis Retinoic Acid. Modern Pathology 8: 102A, 1995.

9. Sellers MT, Singer A, Maller E, Olthoff K, Jacobowski D, Shaked A. “Late

Acute Rejection and Progression to Chronic Rejection in Pediatric Liver Recipients.” Proceedings of the Sixteenth International Congress of the Transplantation Society. Barcelona, Spain, August 1996.

10. Eckhoff DE, McGuire BM, Young CJ, Sellers MT, Frenette L, Hudson Sl,

Contreras J, Bynon S. Race: A Critical Factor in Organ Donation, Patient Referral and Selection, and Orthotopic Liver Transplantation? Transplantation 65 Supplement: 147, May 1998.

11. Bynon JS, Eckhoff DE, Sellers MT, Benfield M, Kohaut E, Hudson SL,


Diethelm A. A Comparison of Adult and Pediatric Renal Transplantation, A Single Center Experience Over 29 Years. Pediatric Transplantation 2(Supplement 1):29-98, July 1998.

12. Eckhoff DE, Sellers MT, Contreras J, Benfield M, Kohaut E, Hudson SL, Diethelm AG, Bynon JS. The Evolving Challenges of Pediatric Renal Transplantation. Pediatric Transplantation 2(Supplement 1):29-98, July 1998.

13. Sellers MT, Noorchasm H, Rostami S, Yokoi Y, Yang Z, Barker C, Naji A. Transient Depletion of B-Lymphocytes Prevents Chronic Cardiac Allograft Rejection. Transplantation 66: S3, October 1998.

14. Yokoi Y, Noorchasm H, Sellers MT, Uchikoshi F, Barker C, Naji A. Origin, Kinetics, and Function of Chimeric B-Lymphocytes in Liver Allografts. Transplantation 66: S60, October 1998.

15. Contreras J, Bilbao G, Krasnykh V, Mikheeva G, Dmitriev I, Belousova N, Eckhoff DE, Sellers MT, Thomas F, Thomas J, Curiel D. Genetically Modified Adenoviral Vector Containing a Heterologous RGD Peptide in the hi Loop of the Fiber Knob Improves Gene Transfer to Vascular Endothelial Cells in Organ Culture. Proceedings of the Sixtieth Annual Meeting of The Society of University Surgeons, February, 1999.

16. Eckhoff DE, McGuire BM, Sellers MT, Contreras J, Frenette L, Hudson SL, Ingram C, Bynon S. The Safety and Efficacy of a Two-Dose Daclizumab (Zenapax) Induction Therapy in Liver Transplant Patients. Transplantation 67: S32, April 1999.

17. Bilbao G, Contreras J, Krasnykh V, Galina M, Dmitriev I, Belousova N, Eckhoff DE, Sellers MT, Thomas F, Thomas J, Curiel D. Genetically Modified Adenoviral Vector Containing a Heterologous RGD Peptide in the HI Loop of the Fiber Knob Improves Gene Transfer to Vascular Endothelial Cells in Organ Culture. Transplantation 67: S206, May 1999.

18. Ray P, Sellers MT, Nadler S, Thomas J. BMS-205820 (A Novel NF-Kappa B

Inhibitor) Prolongs Survival of Rat Cardiac Allografts After a Short Course of Cyclosporine. Transplantation 67: S597, May 1999.

19. Sellers MT*, Hudson SL, Young, CJ, Bynon JS, Eckhoff DE, Gallichio MH,

Deierhoi, MH, Diethelm AG, Thompson JA. Improved Outcomes in Cadaveric Renal Allografts with Pulsatile Preservation. Transplantation 67:S592, May 1999.

20. Smythies L, Sellers MT, Graham M, Smith P. Macrophages from Uninflamed

Human Intestine Produce Little or No Inflammatory Cytokines. Gastroenterology 116: A821, 1999.


21. Frenette L, Smith B, Cross C, Contreras J, Sellers MT, Bynon JS, Eckhoff

DE. Ionized Hypomagnesemia in Orthotopic Liver Transplantation: Do We Need to Treat It? Canadian Journal of Anaesthesia 46: A44, 1999.

22. Gang M, Barnum M, Sellers MT, Smith PD. HIV-1 Receptor and Co-Receptor Distribution on Human Intestinal Mucosal Cells. Immunology Letters 69: 35, 1999.

23. Smythies LE, Sellers MT, Graham M, Smith PD. Intestinal Macrophages Show Markedly Down Regulated Cytokine Production and May Be Derived from CD14- Blood Monocytes. Immunology Letters 69: 112, 1999.

24. Arguedas MR, Mcguire BM, Fallon MB, Abrams GA, Van Leeuwen DJ, Bynon S, Eckhoff D, Sellers M, Bloomer JR. The use of screening and preventive therapies for esophageal varices in patients referred for evaluation of orthotopic liver transplantation. Hepatology. 30(4 Part 2): 215a, September1999.

25. Smith PD, Meng G, Sellers MT, Mosteller-Barnum M, Rogers TS, Shaw GM. Lymphocytes, Not Macrophages, are the Primary Target Cell for HIV-1 in the Intestinal Mucosa. Proceedings of the 4th International Workshop on HIV, Cells of Macrophage Lineage, and other Reservoirs, December 1999.

26. Sellers MT, McGuire BM, Eckhoff DE, Hudson SL, Bynon JS. Feasibility of Steroid Withdrawal in Liver Transplantation – An Experience with 288 Patients. Transplantation 69: S389, April 2000.

27. Singer AL, Kim HC, Sellers MT, Cuy R, Friedman D, Higuchi N, Dugan N, Rand EB, Maller E, Olthoff KM, Shaked A. The Use of Plasmapheresis for the Management of Acute Hepatic Failure in the Pediatric Population. Transplantation 69: S275, April 2000.

28. Singer AL, Sellers MT, Maller E, Rand EB, Higuchi N, Zamir G, Markmann J, Shaked A, Olthoff KM. Variables Affecting Graft Function and Quality of Life 1 vs >5 Years After Pediatric Liver Transplantation. Transplantation 69: S166, April 2000.

29. Smythies LE, Barnum MM, Sellers MT, Smith PD. Resident Intestinal Macrophages Exhibit Unique Phenotype and Down-regulate Inflammatory Cytokine Production. Proceedings of the 2001 Keystone Symposium – Macrophage Activation and Deactivation, January 2001.

30. Sellers MT, Haustein SV, McGuire BM, Eckhoff DE, Jones CJ, Hudson SL, Bynon JS. Incidence and Multivariate Analysis of Risk Factors for Chronic Rejection of Hepatic Allografts. Liver Transplantation 7:C82, 2001.

31. Sellers MT, Haustein SV, McGuire BM, Bynon JS, Eckhoff DE. Impact of


Recipient Noncompliance on Chronic Rejection of Liver Allografts. Proceedings of Transplant Immunosuppression 2001: The Compleat Care of the Transplant Recipient. October 2001.

32. Haustein SV, McGuire BM, Eckhoff DE, Hudson SL, Bynon JS, Sellers MT. Impact of Noncompliance and Donor/Recipient Race Matching on Chronic Liver Rejection. Proceedings of the 2nd International Congress on Immunosuppression. December 2001.

33. Sellers MT, McGuire BM, Haustein SV, Bynon JS, Hudson SL, Eckhoff DE. Long-term follow-up of Daclizumab Induction in Liver Transplant Recipients. American Journal of Transplantation (supplement 3) 2: 208. April 2002.

34. Haustein SV, Sellers MT. Characteristics Associated with (Un)Willingness to be an Organ Donor: Results of a Public Survey. American Journal of Transplantation (supplement 3) 2: 208. April 2002.

35. Sellers M, Velidedeoglu E, Bloom R, Markmann J, Naji A, Grossman R, Markmann J. Outcome of Expanded Criteria Donor Kidneys Transplanted at a Single Center – Resource Utilization and Long-term Function. American Journal of Transplantation (supplement 5) 3: 230. May 2003.

36. Bloom RD, Sayer G, Mange K, Doyle A, Goral S, Grossman RA, Naji A, Markmann J, Sellers M, Reddy R. Long-term Outcome of Hepatitis C Virus (HCV)-infected Kidney Recipients without Pre-transplant Diabetes. American Journal of Transplantation (supplement 5) 3: 503, May 2003.

37. Bloom RD, Sayer GT, Constantinescu S, Fa K, Goral S, Doyle AM, Naji A, Markmann JF, Grossman RA, Sellers MT. Increased mortality in hepatitis C virus (HCV)+ kidney recipients is associated with pre-existing diabetes (DM). American Journal of Transplantation (supplement 8) 4: 202, March 2004.

38. Abt P, Frank A, Stephenson GR, Sellers MT. Factors associated with survival of non-heart-beating donor kidneys. American Journal of Transplantation (supplement 8) 4: 324, March 2004.

39. Frank AM, Deng S, Thambi-Pillai T, Velededeoglu E, Desai NM, Huang X, Lian MM, Mohiuddin MM, Bae YS, Stephenson GR, Abt PL, Sellers MT, Barker CF, Naji A, Markmann JF. Comparison of whole organ pancreas and isolated islet transplantation for type 1 diabetes. American Journal of Transplantation 4(supplement 8): 552-553, March 2004.

40. Mange KC, Doyle A, Goral S, Sellers M, Bloom R. Impact on Clinical

Studies of the Choice of Equations to Estimate Renal Function. American Journal of Transplantation (supplement 8) 4: 601, March 2004.


41. Goral S, Bloom R, Doyle A, Grossman R, Naji, A, Sellers M, Markmann J, Kamoun M. Managing a Large Kidney Transplant Waiting List: Impact of sensitization to HLA Antigens and Patient’s Listing Status on Waiting Time. American Journal of Transplantation 5 (Supplement 11): 350, May 2005.

42. Goral S, Eren P, Bloom RD, Doyle AM, Grossman RA, Israni A, Naji A, Sellers MT, Markmann JF, Kearns J, Kamoun M. Impact of sensitization to HLA class I and class II antigens on receiving a second kidney transplant after a failed graft: report from a transplant center using a stringent HLA crossmatching strategy. American Journal of Transplantation 5 (Supplement 11): 351, May 2005.

43. Frank AM, Markmann J, Yeh H, Porrett PM, Huang XL, Velidedeoglu E, Mohiuddin MM, Deng S, Sellers MT, Naji A, Shaked A, Markmann JF. Kidney transplantation in type 1 diabetics: an analysis of 15 years of OPTN data. American Journal of Transplantation 5 (Supplement 11): 410-411, May 2005.

44. Eren P, Goral S, Bloom R, Doyle A, Grossman R, Israni A, Naji A, Sellers M,

Markmann J, Kearns J, Kamoun M. Impact of sensitization to HLA class I and class II antigens on receiving a second kidney transplant after a failed graft (Proceedings of the XLII Congress, European Renal Association; June 2005)

45. Yeh H, Abrams J, Porrett P, Sellers M, Naji A, Shaked A, Bortecen K, Hasz

R, Markmann J. Expedited Cross-matching for Marginal Kidneys Decreases Cold Ischemia Time and Improves Function. Transplantation 82 Supplement 3: 918-919, July 2006.

46. Johnson M, Tan M, Pollinger H, Sellers M, Cross R, Scouller T, Logen-

Bossie A, Williams S, Wolf J, Whelchel J, Zayas C. Ureteral Stents in Renal Transplantation: BK Friend or Foe? American Journal of Transplantation 9 (Supplement 2): 422, May 2009.

47. Johnson M, Tan M, Pollinger H, Sellers M, Cross R, Scouller T, Logan-Bossie A, Williams S, Wolf J, Whelchel J, Zayas C. IVIG Therapy in Positive Crossmatch Kidney Transplants is Associated with a Decreased Incidence of Polyomavirus Infection. American Journal of Transplantation 9 (Supplement 2): 426, May 2009.

48. Sellers M, Kegley K, Shrestha R, Johnson M, Bruno C, Tan M, Pollinger H,

Citron S. Precision transarterial chemoembolization for hepatocellular carcinoma: histologic efficacy in transplanted patients and safety in advanced cirrhotics. American Journal of Transplantation 9 (Supplement 2): 444, May 2009.


49. Pollinger H, Tan M, Wolf J, Johnson M, Sellers M, Cross R, Bray R, Gebel H, Zayas C, Whelchel J. Positive Crossmatch Kidney Transplantation in a Non-academic Transplant Program: Is It Feasible? American Journal of Transplantation 9 (Supplement 2): 561, May 2009.

50. Pollinger H, Tan M, Wolf J, Johnson M, Sellers M, Cross R, Bray R, Gebel H, Zayas C, Whelchel J. Positive Cross-Match Kidney Transplantation in a Non-Academic Transplant Program: Is it Feasible? (2009 American Transplant Congress; May 2009)

51. Johnson M, Sellers M, Bruno C, Kegley K, Tan M, Pollinger H, Galambos M, Cross R, Jones J, Sutton P, Rubin R, Shrestha R. Impact Of Rapamycin After Liver Transplantation. (2009 American Transplant Congress; May 2009)

52. Panjala C, Stein L, Bruno C, Tan M, Pollinger H, Sellers M, Johnson M,

Shrestha R. Utility of Pre-LT Locoregional Therapy for HCC in UNOS Regions Where Waiting Time for LT Is Historically Shorter American Journal of Transplantation 11 Supplement 2: 114, April 2011.

53. L. Stein, C. Panjala, K. Kegley, M. Sellers, M. Tan, H. Pollinger, C. Bruno, R. Shrestha, M. Johnson. Impact of Early Sirolimus Use on Fibrosis Progression and Graft Survival in HCV Liver Allograft Recipients: A Single Center Experience. American Journal of Transplantation 11 Supplement 2: 274, April 2011.

54. Johnson M, Sellers M, Tan M, Pollinger H, Cross R, Sutton P, Berry C, Panjala C, Stein L, Bruno C, Shrestha R. Routine Use of Abdominal CT Scans After Biliary Leaks in Liver Transplant Recipients: Is it Clinically or Cost Effective? American Journal of Transplantation 11 Supplement 2: 329, April 2011.

55. Sellers M, Kegley K, Pollinger H, Stein L, Shrestha R, Johnson M, Arepally A, Citron S. Multivariate Analysis of Prognostic Factors following Chemoembolization with Doxorubicin-eluting Beads (DEB-DOX) for Hepatocellular Carcinoma. Proceedings of the Sixth International Liver Cancer Association Annual Conference; September 2012.

56. Sellers M, Kegley K, Pollinger H, Stein L, Shrestha R, Johnson M, Arepally A, Citron S. Comparison of Doxorubicin-eluting Bead Chemoembolization and Resection for Early Hepatocellular Carcinoma. (Proceedings of the Sixth International Liver Cancer Association Annual Conference; September 2012)

57. Sellers M, Alperin M. Multivariate Analysis of Factors Associated with Willingness to be an Organ Donor – a Basis for Organ Donation Advocacy/Awareness. Proceedings of the 141st APHA Annual Meeting and


Expo; November 2013.

58. Mulloy, M, Cross R, Tan M, Sellers M, Johnson M, Ommert T, D'Annunzio S, Pollinger H. Protocol-based Reduction in Narcotic Use and Length of Stay Following Robotic Live Donor Nephrectomy. American Journal of Transplantation 14 Supplement 3: 602, June 2014.

59. Sellers M, Lee R, Turgeon N, Pearson T, Davis J, Lilly K, McDonald B,

Langley L. Liver-only Deceased Donors – Are they Worth Pursuing? American Journal of Transplantation 17(suppl2):26, 2017.

60. Sellers M, Alperin M. Multivariate Analysis of Factors Predicting Willingness

to be an Organ Donor – Targets for Intervention. American Journal of Transplantation 17(suppl2):90, 2017.

61. Sellers M, Lee R, Owens Z, Turgeon N, Pearson T, Davis J, Lilly K,

McDonald B, Langley L. Excellent Outcomes following Transplantation of Livers from Over 400 Single-Organ Donors. Proceedings of the Association of Organ Procurement Organization's 2017 Annual Meeting, 2017.

62. Sellers MT, McGinnis HS, Alperin M, Sweeney JF, Dodson TF. Deterrents to

Organ Donation – A Multivariate Analysis of 766 Survey Respondents. Proceedings of the 129th Annual Meeting of the Southern Surgical Association.

63. Sellers M, Lawrence P, Marshman D, Lilly K, Davis J, Langley L. “Outcomes

from Livers Transplanted from Deceased Donors with End-Stage Renal Disease.” Proceedings of the 27th International Congress of The Transplantation Society. Madrid, Spain, June 2018 (in press).

64. Lehr L, Davis J, Sellers M, Lawrence P. “A Systems-Based Approach to

Increasing Organs Transplanted: One Organ Procurement Organization’s experience.” Proceedings of the 27th International Congress of The Transplantation Society. Madrid, Spain, June 2018 (in press).

65. Bell RD, Howard B, Lawrence P, Lilly K, Sellers M, Davis J. “Success of a

‘Multicultural Donation Education Program’ to Increase African-American Organ Donation in a Donor Service area with a High African-American Population.” Proceedings of the 27th International Congress of The Transplantation Society. Madrid, Spain, June 2018 (in press).

66. McDonald B, Lawrence P, Sellers M, Wade S, Davis J. “The Great

Recession and the Importance of Donation After Circulatory Determination of Death (DCDD).” Proceedings of the 27th International Congress of The Transplantation Society. Madrid, Spain, June 2018 (in press).


d. Other Publications:

1. Stein LL, Sellers MT. Comment on Mehta et al. Additional treatment

outcomes for patients with infiltrative hepatocellular carcinoma. (Letter to the Editor) Clinical Gasroenterology and Hepatology, 11:1673, 2013.

2. Kamoun M, Sellers MT. Changing the priority for HLA matching in kidney transplantation. (Letter to the Editor) New England Journal of Medicine, 350(20):2096, 2004.

3. Marty T. Sellers. Piedmont Hospital Launches Multidisciplinary Liver Cancer Treatment Program. Physicians Practice, January 2007.

4. Marty T. Sellers, Mark W. Johnson. “A Healthy Liver for Yourself.” Atlanta Woman, May 2008.

5. Marty T. Sellers, Steven J. Citron. “Randomized Clinical Trial for Patients with Hepatocellular Carcinoma being Conducted at Piedmont Hospital.” Physicians Practice, March 2009.

6. Marty T. Sellers. “Multidisciplinary treatment of hepatocellular carcinoma (HCC) at Piedmont Hospital.” Physicians Practice, March 2010.

7. Marty T. Sellers, Harrison S. Pollinger. “Liver Transplantation with Curative Intent for Hepatobiliary Malignancies.” Atlanta Medicine, 84:8-10, 2013.

30. Contributions Not Otherwise Noted:

1. Lecture: “Early Renal Dysfunction in Liver Transplantation: The Use of

CellCept and Zenapax as a Calcineurin-Inhibitor Sparing Agent.” Roche Northeast Regional Liver Advisory Board Meeting, Philadelphia, Pennsylvania. November 5, 2003.

2. Lecture: “Liver Cancer.” Airport Area Kiwanis Club, Atlanta, Georgia. April 11, 2007.

3. Lecture: “Liver Cancer.” Southlake Kiwanis Club, Morrow, Georgia. April 17, 2007.

4. Lecture: “Liver Cancer.” Metro Atlanta Kiwanis Club. Atlanta, Georgia. July 17, 2007.

5. Lecture: “Liver Cancer.” Historic Roswell Kiwanis Club. Atlanta, Georgia. July 19, 2007.

6. Lecture: “Staying Healthy: Transplant Checklist.” Georgia Transplant Foundation, Trends in Transplantation. Rome, Georgia. July 21, 2007.

7. Lecture: “Liver Cancer.” Buckhead Kiwanis Club. Atlanta, Georgia. July 30, 2007.

8. Lecture: “Staying Healthy: Transplant Checklist.” Georgia Transplant


Foundation’s Trends in Transplantation. Rome, Georgia. August 2, 2008. 9. Lecture: “Transplantation: Past, Present and Future.” Georgia Transplant

Foundation’s Trends in Transplantation. Columbus, Georgia. April 18, 2009. 10. Lecture: “The Liver Transplant Journey.” Georgia Transplant Foundation,

Trends in Transplantation. Augusta, Georgia, August 25, 2012. 11. Recognized as a “Best Doctor in America,” (bestdoctors.com) 2013, 2014,

2015, 2016. 12. Lecture: “Liver Transplantation.” Georgia Transplant Foundation’s Trends in

Transplantation. Atlanta, Georgia. October 25, 2014. 13. Member, Rollins School of Public Health Alumni Board, 2016-present.

a. Career Development Committee, 2016-2017. b. Alumni Giving Committee, 2017-present.

14. Volunteer: Rollins School of Public Health Mock Interview Session, October 19, 2016. I interviewed multiple students as if they were applying for a post-Master’s job and provided feedback on their performance and advice for their eventual real interview(s).

15. Volunteer: Mentor for Rollins School of Public Health first-year students, 2017-present.

emory university school of medicine standard … t. sellers md_cv.pdfemory university school of...

Documents